Latigo Biotherapeutics filed its S-1 on July 17, 2026, targeting a $1.08 billion post-IPO valuation and up to $288 million in proceeds via 16 million shares priced at $16–$18, following a $150 million Series B at a $526 million post-money valuation in March 2025. Recent positive Phase 2 abdominoplasty data for its lead Nav1.8 inhibitor LTG-001, published in the New England Journal of Medicine on July 29, and planned Phase 3 trials in the second half of 2026 have reinforced pipeline momentum in a rebounding biotech IPO environment. With outcomes clustered between roughly $850 million and $1.45 billion at 43–50% implied probabilities, traders weigh clinical catalysts against sector volatility, dilution risks, and broader market appetite for pre-revenue biotechs.
Polymarket ডেটা রেফারেন্স করে পরীক্ষামূলক AI-জেনারেটেড সারাংশ। এটি ট্রেডিং পরামর্শ নয় এবং এই মার্কেট কীভাবে রেজলভ হয় তাতে কোনো ভূমিকা রাখে না। · আপডেটেডLatigo Biotherapeutics IPO Closing Market Cap
Latigo Biotherapeutics IPO Closing Market Cap
No IPO before October 2026 5.2%
<$850M 0
$850M-$1B 0
$1B-$1.15B 0
নতুন
নতুন
Aug 7, 2026
<$850M
45%
$850M-$1B
46%
$1B-$1.15B
50%
$1.15B-$1.3B
46%
$1.3B-$1.45B
47%
$1.45B+
46%
No IPO before October 2026
5%
No IPO before October 2026 5.2%
<$850M 0
$850M-$1B 0
$1B-$1.15B 0
নতুন
নতুন
Aug 7, 2026
<$850M
$80 Vol.
45%
$850M-$1B
$211 Vol.
46%
$1B-$1.15B
$111 Vol.
50%
$1.15B-$1.3B
$86 Vol.
46%
$1.3B-$1.45B
$45 Vol.
47%
$1.45B+
$75 Vol.
46%
No IPO before October 2026
$53 Vol.
5%
This market will resolve based on Latigo Biotherapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 7 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Latigo Biotherapeutics filed its S-1 on July 17, 2026, targeting a $1.08 billion post-IPO valuation and up to $288 million in proceeds via 16 million shares priced at $16–$18, following a $150 million Series B at a $526 million post-money valuation in March 2025. Recent positive Phase 2 abdominoplasty data for its lead Nav1.8 inhibitor LTG-001, published in the New England Journal of Medicine on July 29, and planned Phase 3 trials in the second half of 2026 have reinforced pipeline momentum in a rebounding biotech IPO environment. With outcomes clustered between roughly $850 million and $1.45 billion at 43–50% implied probabilities, traders weigh clinical catalysts against sector volatility, dilution risks, and broader market appetite for pre-revenue biotechs.
This market will resolve based on Latigo Biotherapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 7 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on August 7 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
মার্কেট ওপেন হয়েছে: Aug 5, 2026, 5:52 AM ET
ভলিউম
$661শেষ তারিখ
Aug 7, 2026মার্কেট ওপেন হয়েছে
Aug 5, 2026, 5:52 AM ETResolver
0x69c47De9D...This market will resolve based on Latigo Biotherapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 7 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Latigo Biotherapeutics filed its S-1 on July 17, 2026, targeting a $1.08 billion post-IPO valuation and up to $288 million in proceeds via 16 million shares priced at $16–$18, following a $150 million Series B at a $526 million post-money valuation in March 2025. Recent positive Phase 2 abdominoplasty data for its lead Nav1.8 inhibitor LTG-001, published in the New England Journal of Medicine on July 29, and planned Phase 3 trials in the second half of 2026 have reinforced pipeline momentum in a rebounding biotech IPO environment. With outcomes clustered between roughly $850 million and $1.45 billion at 43–50% implied probabilities, traders weigh clinical catalysts against sector volatility, dilution risks, and broader market appetite for pre-revenue biotechs.
This market will resolve based on Latigo Biotherapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 7 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on August 7 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
ভলিউম
$661শেষ তারিখ
Aug 7, 2026মার্কেট ওপেন হয়েছে
Aug 5, 2026, 5:52 AM ETResolver
0x69c47De9D...Latigo Biotherapeutics filed its S-1 on July 17, 2026, targeting a $1.08 billion post-IPO valuation and up to $288 million in proceeds via 16 million shares priced at $16–$18, following a $150 million Series B at a $526 million post-money valuation in March 2025. Recent positive Phase 2 abdominoplasty data for its lead Nav1.8 inhibitor LTG-001, published in the New England Journal of Medicine on July 29, and planned Phase 3 trials in the second half of 2026 have reinforced pipeline momentum in a rebounding biotech IPO environment. With outcomes clustered between roughly $850 million and $1.45 billion at 43–50% implied probabilities, traders weigh clinical catalysts against sector volatility, dilution risks, and broader market appetite for pre-revenue biotechs.
Polymarket ডেটা রেফারেন্স করে পরীক্ষামূলক AI-জেনারেটেড সারাংশ। এটি ট্রেডিং পরামর্শ নয় এবং এই মার্কেট কীভাবে রেজলভ হয় তাতে কোনো ভূমিকা রাখে না। · আপডেটেড
বাহ্যিক লিংক থেকে সাবধান।
বাহ্যিক লিংক থেকে সাবধান।
সচরাচর জিজ্ঞাসা